<DOC>
	<DOCNO>NCT02087722</DOCNO>
	<brief_summary>KI1001 ( Circadin® , Prolonged release tablet contain melatonin ) show efficacy improve sleep quality 55 year old primary insomnia patient . This 2nd bridging study investigate efficacy safety KI1001 ( Circadin® ) Korean patient .</brief_summary>
	<brief_title>Efficacy Safety KI1001 Treatment ≥ 55 Years Old Insomnia Patients</brief_title>
	<detailed_description>This study conduct use randomise , double-blind , placebo control parallel group design , single-blind placebo period . Primary insomnia patient age 55 screened entry study . After placebo run-in period , Patients enter 3 week double-blind treatment period . Primary parameter quality sleep , secondary parameter include get sleep , awaken sleep , behavior follow wakefulness , quality day night , sleep latency quality life .</detailed_description>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<criteria>Male female age ≥55 year Suffering primary insomnia accord DSMIV criterion consultation complaint Good anticipate compliance Written inform consent participate study give patient voluntarily Confirmed diagnosis primary insomnia sleep history questionnaire Established baseline pathology A good compliance twoweeks placebo runin period define 70 % 130 % prescribed tablet Correct use Sleep Diary KMLSEQ According DSMIV , subject belong follow group exclude : 780.59 ( breathe relate sleep disorder ) ; 307.45 ( circadian thyrhm sleep disorder ) ; 307.47 ( dyssomnia otherwise specify ) ; 780.XX ( sleep disorder due general medical condition ) Known suspect hypersensitivity exogenous melatonin melatonin receptor agonist Known positive serology human immunodeficiency virus ( HIV ) I antibodies HIV II antibody Known chronic active viral hepatitis Drug abuse history drug abuse ( include alcohol ) History severe pathology likely recur immediately study History severe cardiac disorder History severe neurological disorder cerebral neurosurgery History severe psychiatric disorder , especially psychosis depression , sismotherapy Depression assess Raskin scale : patient total score ≥ 6 include Anxiety assess Covi scale : patient total score ≥ 6 included Dementia assess Mini Mental State ( MMS ) : patient score ≤ 24 26 ( depend socioeducational level patient ) include Neuropsychiatric pathology might interfere insomnia , patient assessment study medication Use psychotropic treatment past 3 month study Use benzodiazepine hypnotic precede two week ( include benzodiazepine ; zopiclone , zolpidem , zaleplon , barbiturate , buspirone hydroxyzine ) All hypnotic treatment use hypnotic allow study Severe pain likely interfere sleep Other sleep disorder accord DSMIV criterion identify numerical ICD 9 code : breathingrelated sleep disorder ( 780.59 ) , circadian rhythm sleep disorder ( 307.45 ) , dyssomnia otherwise specify ( 307.47 ) sleep disorder ( 780.xx ) Serious disease could interfere patient assessment Organic pathology stabilise might interfere sleep , patient assessment study medication Intercurrent acute chronic somatic disease likely interact sleep ( example : chronic pain aetiology , benign prostatic hypertrophy likely require surgery come six month ) Any concomitant document progressive disease likely interfere conduct study Any medical condition might interfere completion study , would adversely affected thereby increase risk patient interfere patient assessment . Patients excessive consumption alcohol , coffee tea Patients irregular lifestyle life pattern ( e.g . shift worker patient likely jet lag ) Patients Body Mass Index 30 obesity Patients take investigational drug within two month precede first dose study drug . Investigational drug define drug marketing authorisation grant country study conduct . Patients receive concomitant treatment permit A positive drug screen ( benzodiazepine opiate ) initial two week placebo runin period</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Primary Insomnia</keyword>
</DOC>